Evolution of the Average Target: Virbac

Evolution of the Target Price: Virbac

Changes in Analyst Recommendations: Virbac

7a.wU0w2oMUhsATdkWVCjmbWnxxNCbJwspT5lfhR0cNjiI.ixUElu5M6rVXGjWhe17JMhc6TUiRt6IQoS_WL35Z9xC1KgeO207Itl4MLg~3022e980beeb6123ece3a692451a1fec
20/08 Cancer vaccines finally garner the spotlight Alphavalue
21/07 Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 Alphavalue
14/07 Where would AI lead Pharma in the long run? Alphavalue
11/05 Virbac continues decline despite positive recommendation Zonebourse
17/04 Virbac: 2026 starts on strong footing Alphavalue
19/03 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
18/03 Virbac in the green following results and outlook Zonebourse
20/01 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
20/01 Stifel Raises Price Target on Virbac Zonebourse
20/01 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
17/25/17 Virbac: Q3 crushed doubts about execution ability Alphavalue
17/25/17 The day the Fed resumed its rate cuts Zonebourse
15/25/15 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
17/25/17 Virbac: A healthy Q2 impresses the markets Alphavalue
03/25/03 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
03/25/03 Virbac: Oddo BHF upgrades stock Zonebourse
17/25/17 Virbac: brokers' advice following quarterly results Zonebourse
16/25/16 Virbac: Stifel remains bullish after quarterly results Zonebourse
16/25/16 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
16/25/16 Virbac: Stifel still buying after Q1 results Zonebourse
17/25/17 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
17/25/17 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
17/25/17 Virbac: Stifel raises its recommendation Zonebourse
17/25/17 Virbac: 2024 top-line goals met; uninspiring 2025 outlook could be raised later Alphavalue
17/25/17 Oddo BHF Downgrades Virbac to Neutral, Cuts PT MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+24.51%
+30.49%
+100.81%
+27.71%
+14.26%
+4.36%
- +16.59%
+17.98%
- +31.77%
Average +29.83%
Weighted average by Cap. +29.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
322.50EUR
Average target price
411.88EUR
Spread / Average Target
+27.71%
High Price Target
440.00EUR
Spread / Highest target
+36.43%
Low Price Target
360.00EUR
Spread / Lowest Target
+11.63%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA